Enovis (NYSE:ENOV) Stock Rating Upgraded by Wall Street Zen

Enovis (NYSE:ENOV) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

A number of other equities analysts have also weighed in on ENOV. Needham & Company LLC increased their target price on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Evercore restated an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. BTIG Research upped their price objective on Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Zacks Research upgraded Enovis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 4th. Finally, UBS Group reissued a “buy” rating and set a $50.00 target price on shares of Enovis in a report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $47.43.

Enovis Stock Performance

Shares of ENOV stock opened at $22.99 on Friday. Enovis has a 52 week low of $21.00 and a 52 week high of $40.69. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -1.11 and a beta of 1.46. The company has a 50-day simple moving average of $23.81 and a 200 day simple moving average of $27.82. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.14. The firm had revenue of $575.76 million for the quarter, compared to analysts’ expectations of $584.30 million. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The business’s revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, sell-side analysts predict that Enovis will post 2.79 earnings per share for the current year.

Insider Buying and Selling at Enovis

In related news, insider Oliver Engert purchased 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average cost of $25.50 per share, for a total transaction of $25,500.00. Following the completion of the purchase, the insider owned 43,640 shares in the company, valued at approximately $1,112,820. This represents a 2.35% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have purchased 4,000 shares of company stock valued at $98,243 in the last three months. 2.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enovis

A number of hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC raised its holdings in Enovis by 12.5% in the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after acquiring an additional 7,072 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Enovis by 37.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after purchasing an additional 73,116 shares in the last quarter. Empowered Funds LLC increased its position in shares of Enovis by 13.0% in the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after purchasing an additional 749 shares during the period. ProShare Advisors LLC acquired a new position in Enovis in the second quarter valued at about $400,000. Finally, Vise Technologies Inc. acquired a new position in Enovis in the second quarter valued at about $208,000. Institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.